Waxman DJ - Search Results

1

Progress and prospects: gene therapy clinical trials (part 2).

Aiuti A, Bachoud-Lévi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, Gao G, High KA, Leen AM, Lemoine NR, McNeish IA, Meneguzzi G, Peschanski M, Roncarolo MG, Strayer DS, Tuszynski MH, Waxman DJ, Wilson JM. Aiuti A, et al. Among authors: waxman dj. Gene Ther. 2007 Nov;14(22):1555-63. doi: 10.1038/sj.gt.3303033. Gene Ther. 2007. PMID: 17984995 Review.

2

Cytochrome p450-based gene therapies for cancer.

Chiocca EA, Waxman DJ. Chiocca EA, et al. Among authors: waxman dj. Methods Mol Med. 2004;90:203-22. doi: 10.1385/1-59259-429-8:203. Methods Mol Med. 2004. PMID: 14657565 Review. No abstract available.

3

Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene.

Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA. Wei MX, et al. Among authors: waxman dj. Hum Gene Ther. 1994 Aug;5(8):969-78. doi: 10.1089/hum.1994.5.8-969. Hum Gene Ther. 1994. PMID: 7948146

4

Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.

Lu H, Chen CS, Waxman DJ. Lu H, et al. Among authors: waxman dj. Cancer Gene Ther. 2009 May;16(5):393-404. doi: 10.1038/cgt.2008.93. Epub 2008 Nov 14. Cancer Gene Ther. 2009. PMID: 19011599 Free PMC article.

5

Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.

Huang Z, Waxman DJ. Huang Z, et al. Among authors: waxman dj. Cancer Gene Ther. 2001 Jun;8(6):450-8. doi: 10.1038/sj.cgt.7700325. Cancer Gene Ther. 2001. PMID: 11498765

6

Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Chen CS, Jounaidi Y, Su T, Waxman DJ. Chen CS, et al. Among authors: waxman dj. Cancer Gene Ther. 2007 Dec;14(12):935-44. doi: 10.1038/sj.cgt.7701092. Epub 2007 Sep 14. Cancer Gene Ther. 2007. PMID: 17853921 Free PMC article.

7

Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.

Doloff JC, Jounaidi Y, Waxman DJ. Doloff JC, et al. Among authors: waxman dj. Cancer Gene Ther. 2011 Mar;18(3):153-66. doi: 10.1038/cgt.2010.52. Epub 2010 Sep 24. Cancer Gene Ther. 2011. PMID: 20865021 Free PMC article.

8

Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.

Huang Z, Raychowdhury MK, Waxman DJ. Huang Z, et al. Among authors: waxman dj. Cancer Gene Ther. 2000 Jul;7(7):1034-42. doi: 10.1038/sj.cgt.7700200. Cancer Gene Ther. 2000. PMID: 10917206

9

Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.

Chen L, Waxman DJ. Chen L, et al. Among authors: waxman dj. Curr Pharm Des. 2002;8(15):1405-16. doi: 10.2174/1381612023394566. Curr Pharm Des. 2002. PMID: 12052216 Review.

10

Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.

Schwartz PS, Chen CS, Waxman DJ. Schwartz PS, et al. Among authors: waxman dj. Cancer Gene Ther. 2003 Aug;10(8):571-82. doi: 10.1038/sj.cgt.7700601. Cancer Gene Ther. 2003. PMID: 12872138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

373 results

Search Page

Filters